These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 2291745)

  • 21. [Study on dissolution test in vitro and bioavailability of oral osmotic pump of verapamil hydrochloride].
    Guo JL; Jing GW; Cao DS; Li YQ; He HY; Ling LX; Li Z
    Yao Xue Xue Bao; 1993; 28(9):714-20. PubMed ID: 8010021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of an in vitro absorption model system for predicting sustained release of verapamil.
    Neubert R; Fahr F; Mäder C; Lücke L; Fries G; Rostock G
    Arzneimittelforschung; 1992 Sep; 42(9):1098-100. PubMed ID: 1445475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Bioavailability of etilefrine from Thomasin and Thomasin sustained-release tablets].
    Haustein KO; Hüller G
    Pharmazie; 1985 Nov; 40(11):776-8. PubMed ID: 2869507
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative pharmacokinetic analysis of novel sustained-release dosage forms of pentoxifylline in healthy subjects.
    Raz I; Ben-David J; Hussein Z; Samara E
    Int J Clin Pharmacol Ther Toxicol; 1988 Apr; 26(4):206-8. PubMed ID: 3403100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of verapamil and norverapamil in patients with hypertension: a comparison of oral conventional and sustained release formulations.
    Jørgensen NP; Walstad RA
    Pharmacol Toxicol; 1988 Aug; 63(2):105-7. PubMed ID: 3186615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of intranasal versus intravenous verapamil bioavailability.
    Watling S; Engelhardt J; Kandrotas R; Gal P; Kroboth P; Smith H; Johnson M
    Int J Clin Pharmacol Ther Toxicol; 1993 Feb; 31(2):100-4. PubMed ID: 8458675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the absorption from three ibuprofen formulations.
    Regazzi BM; Rondanelli R; Ciaroelli L; Bartoli AL; Rampini A
    Int J Clin Pharmacol Res; 1986; 6(6):469-73. PubMed ID: 3804520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The bioavailability of a slow-release verapamil formulation.
    Norris RJ; Muirhead DC; Christie RB; Devane JG; Bottini PB
    Br J Clin Pract Suppl; 1985 Jun; 42():9-16. PubMed ID: 3929828
    [No Abstract]   [Full Text] [Related]  

  • 29. The effect of food on the bioavailability of ibuprofen and flurbiprofen from sustained release formulations.
    Pargal A; Kelkar MG; Nayak PJ
    Biopharm Drug Dispos; 1996 Aug; 17(6):511-9. PubMed ID: 8866042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of extended-release and immediate-release formulations of galantamine at steady state in healthy volunteers.
    Zhao Q; Janssens L; Verhaeghe T; Brashear HR; Truyen L
    Curr Med Res Opin; 2005 Oct; 21(10):1547-54. PubMed ID: 16238894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. St John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism.
    Tannergren C; Engman H; Knutson L; Hedeland M; Bondesson U; Lennernäs H
    Clin Pharmacol Ther; 2004 Apr; 75(4):298-309. PubMed ID: 15060508
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Plasma levels and noninvasive hemodynamic profile of slow release verapamil (240 mg). A multicenter study].
    Vulpis V; Seccia TM; Ricci S; Pirrelli A
    Riv Eur Sci Med Farmacol; 1993; 15(5-6):227-35. PubMed ID: 7761676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PK/PD modelling of high-dose diltiazem--absorption-rate dependency of the hysteresis loop.
    Luckow V; Della Paschoa O
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):418-25. PubMed ID: 9352390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioavailability of controlled-release metoclopramide. 2nd communication: multiple dose study.
    Beckett AH; Behrendt WA; Hadzija BW
    Arzneimittelforschung; 1987 Feb; 37(2):224-8. PubMed ID: 3580027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bioavailability of controlled-release metoclopramide. 1st communication: single dose study.
    Beckett AH; Behrendt WA; Hadzija BW
    Arzneimittelforschung; 1987 Feb; 37(2):221-4. PubMed ID: 3580026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma levels and urinary excretion of verapamil, norverapamil, N-dealkylverapamil (D617), N-dealkylnorverapamil (D620) following oral administration of a slow-release preparation.
    Barbieri E; Padrini R; Piovan D; Toffoli M; Cargnelli G; Trevi G; Ferrari M
    Int J Clin Pharmacol Res; 1985; 5(2):99-107. PubMed ID: 4018947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
    Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
    Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bioavailability study of two different verapamil formulations.
    Horne C; Stenzhorn G; Blume H; Knauf H; Mutschler E
    Arch Pharm (Weinheim); 1992 Aug; 325(8):531-6. PubMed ID: 1417461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Normal and slow-release formulations of bezafibrate: a comparative pharmacokinetic study in man.
    Gandini R; Assereto R; Castoldi D; Cunietti E; Garanzelli P; Monzani W
    Int J Clin Pharmacol Res; 1987; 7(2):149-55. PubMed ID: 3583496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and pharmacodynamics of two formulations of verapamil.
    Hla KK; Henry JA; Latham AN
    Br J Clin Pharmacol; 1987 Nov; 24(5):661-4. PubMed ID: 3435694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.